Finally A FIBCO, Regeneron Sets Its Sights On Eylea And Beyond
The better-than-expected performance of Regeneron’s first significant commercial drug, Eylea, has fueled the company’s ambitions to build a sustainable, risk-adjusted portfolio based on a mix of best-in-class and first-in-class new drugs. Getting to this point took a mixture of perseverance, astute science, opportunism, and savvy partnering.
You may also be interested in...
Regeneron and Geisinger’s new collaboration to identify genetic variants and apply that knowledge to drug discovery and patient care is pharma’s most ambitious effort to date to exploit next-generation genomics, but its impact on drug discovery productivity won’t be known for years.
How best to tap scientific innovation? Identifying the top ‘true’ innovators and nurturing them and their ideas in-house may work for biotechs like Regeneron, but the fruits of such efforts are too rare to be reliable growth engines for big companies like Pfizer. That’s one takeaway from a lively R&D chiefs debate at Elsevier’s PSA 2013.
A typical mature biotech company evolves over four discrete stages – from the initial discovery stage through the preclinical and early clinical stage, then to the late clinical trials and commercial build-out – before it becomes a fully integrated biotech company. The final transition is a make-or-break scenario for any biotech company, and high-quality marketed products alone don’t guarantee a successful transformation.